Intervacc AB logo

Intervacc AB (2E9)

Market Open
7 Aug, 20:00
XSTU XSTU
0. 09
-0
-3.1915%
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
- Eps
0.09
Previous Close
Add Transaction
Day Range
0.08 0.09
Year Range
0.03 0.13
Want to track 2E9 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

2E9 trading today lower at €0.09, a decrease of -3.1915% from yesterday's close, completing a monthly decrease of -6.0888% or -€0.01. Over the past 12 months, 2E9 stock gained 157.0621%.
2E9 is not paying dividends to its shareholders.
The last earnings report, released on May 13, 2026, exceeded the consensus estimates by 0.06%. On average, the company has surpassed earnings expectations by 0.13%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

2E9 Chart

Intervacc AB (2E9) FAQ

What is the stock price today?

The current price is €0.09.

On which exchange is it traded?

Intervacc AB is listed on XSTU.

What is its stock symbol?

The ticker symbol is 2E9.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Intervacc AB ever had a stock split?

No, there has never been a stock split.

Intervacc AB Profile

Biotechnology Industry
Healthcare Sector
Mr. Jonas Sohlman CEO
XSTU Exchange
SE0009607252 ISIN
Sweden Country
15 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Intervacc AB (publ) is at the forefront of veterinary vaccine development, focusing on delivering innovative solutions for animals in Sweden. Since its inception in 1983, the company has been dedicated to addressing the critical health challenges faced by livestock and companion animals through advanced vaccine technologies. Based in Hägersten, Sweden, Intervacc AB combines scientific research with market insights to develop vaccines that not only meet the health requirements of animals but also support the needs of farmers and pet owners. Besides its strong emphasis on research and development, the company extends its expertise to the marketing and distribution of a variety of veterinary products across the Nordic markets, encompassing a range of therapeutic areas for swine, horses, cattle, and sheep.

Products and Services

  • Strangvac
  • A pioneering vaccine developed for horses to combat equine strangles, a prevalent and infectious equine disease caused by the bacterium Streptococcus equi. Strangvac represents Intervacc AB’s commitment to advancing animal health through innovative biotechnological solutions.

  • INV274
  • Targets the pressing need for effective treatment against Streptococcus suis, a significant pathogen in swine that leads to a range of health issues in piglets. INV274 comprises antigens formulated to stimulate a robust immune response, thereby offering a preventive strategy against this disease.

  • INV412
  • A multi-component vaccine designed to protect dairy cows from multiple bacteria known to cause mastitis, a major concern for the dairy industry due to its impact on milk production and animal welfare. INV412 demonstrates Intervacc AB’s multidisciplinary approach to addressing complex diseases with profound economic impacts.

Alongside its product pipeline, Intervacc AB actively participates in the Nordic veterinary market, distributing a comprehensive array of pharmaceuticals and vaccines tailored for swine, horses, cattle, and sheep. This includes not only its own developed products but also a curated selection of veterinary solutions aimed at enhancing the overall health and productivity of livestock and companion animals.

Contact Information

Address: Västertorpsvägen 135
Phone: 46 8 12 01 06 00